结合组效应:从非胺酸沃里诺斯塔特类似物中吸取的教训
Silke Geurs1,2, Dorien Clarisse2,3, Karolien De Bosscher2,3
1SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium.
Journal of medicinal chemistry
|June 5, 2023
概括
研究人员正在探索除酸之外的新结合组 (ZBGs) 对于激素脱乙酶抑制剂 (HDACi). 这种方法旨在提高癌症和炎症疾病治疗的安全性和有效性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 基因组脱乙酶 (HDACs) 是癌症,炎症和神经退行性疾病的关键药物标.
- 基于酸的HDAC抑制剂 (HDACi) 面临安全问题,推动了对替代结合组 (ZBG) 的研究.
- 沃里诺斯塔特 (suberoylanilide hydroxamic acid) 是一种经过临床批准的HDACi,也是ZBG比较的基准.
研究的目的:
- 为提供用于HDAC抑制剂的非酸ZBGs的概述.
- 为了能够直接比较各种ZBGs的抑制潜力和生物效应.
- 讨论ZBG选择的策略,其属性,活动和负债.
主要方法:
- 在利诺斯塔特类似物中纳入的非酸ZBGs的审查和分析.
- 基于已公布的数据,对不同ZBG进行比较评估.
- 讨论ZBG选择策略及其对抑制剂概况的影响.
主要成果:
- 鉴定和分类了各种非酸ZBGs用于抑制HDAC.
- 证明了ZBG修改如何影响HDAC抑制剂的强度和选择性.
- 突出了不同ZBG之间关于活动和潜在负债的权衡.
结论:
- 非酸ZBGs为开发更安全,更有效的HDAC抑制剂提供了一个有希望的途径.
- 在类似的化学支架 (vorinostat类似物) 中直接比较ZBGs对于理解结构-活性关系至关重要.
- 对新型ZBG的进一步研究是有必要的,以克服当前HDACi疗法的局限性.
相关概念视频
Protein-Drug Binding: Mechanism and Kinetics
661
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
661
Drug Binding to Blood Components
183
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
183
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
356
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
356
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
209
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
209
Factors Affecting Protein-Drug Binding: Protein-Related Factors
203
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
203
Factors Affecting Protein-Drug Binding: Drug Interactions
208
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
208


